Authors:
Milena Lopicic Institute of Public Health of Montenegro, Podgorica, Montenegro

Search for other papers by Milena Lopicic in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-6922-9514
,
Janja Raonic Clinical Centre of Montenegro, Podgorica, Montenegro

Search for other papers by Janja Raonic in
Current site
Google Scholar
PubMed
Close
,
Marija Antunovic Clinical Centre of Montenegro, Podgorica, Montenegro

Search for other papers by Marija Antunovic in
Current site
Google Scholar
PubMed
Close
,
Biljana Milicic University of Belgrade, Belgrade, Serbia

Search for other papers by Biljana Milicic in
Current site
Google Scholar
PubMed
Close
, and
Gordana Mijovic Institute of Public Health of Montenegro, Podgorica, Montenegro

Search for other papers by Gordana Mijovic in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Cervical cancer (CC) is the third leading cause of death in women in Montenegro. Human papillomavirus (HPV) is the causative agent of CC however, HPV genotype distribution varies across regions. This study examined the distribution and impact of vaccine-related high-risk (HR)-HPVs on the development of cervical dysplasia in Montenegrin women. A total of 187 women who had a clinical indication for cervical biopsy were enrolled. Based on histopathological findings, women were classified into 2 groups, with and without dysplasia. HR-HPV was detected by real-time PCR. Twelve HR-HPV genotypes were detected in 40.6% of cervical samples. The 7 most prevalent HR-HPVs in order of decreasing frequency were HPV 16 (39.5%), 45 (23.7%), 31 (21.0%), 33 (17.1%), 18 (6.6%), 52 (6.6%), and 58 (6.6%), all of them are targeted by nonavalent vaccine. Vaccine-related HR-HPVs had a higher prevalence (92.1%) than the other HR-HPVs detected in HR-HPV–positive samples. Among HR-HPV–positive women, HPV 16 and 33 were more common in women with dysplasia than in those without dysplasia (HPV 16: 28.9 vs 7.2%; HPV 33: 11.8 vs 3.6%). HPV 16 was the most common HR-HPV genotype in cervical samples, followed by HPV 45, 31, 33, 18, 52, and 58. HPV 16 and 33 were shown to be associated with the development of cervical dysplasia. These results indicate that prophylactic nonavalent vaccine can potentially prevent approximately 90% of HR-HPV infections and 60% of cervical dysplasia cases in Montenegrin women.

  • 1.

    Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394424.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Shwe M-M , Harano T , Okada S , Win A-A , Aye K-S , Thu H-M , et al. Prevalence of high-risk human papillomavirus (HR-HPV) infection among women with normal and abnormal cervical cytology in Myanmar. Acta Med Okayama 2014; 68(2): 7987. https://doi.org/10.18926/AMO/52404. PMID: 24743783.

    • Search Google Scholar
    • Export Citation
  • 3.

    Poljak M , Seme K , Maver PJ , Kocjan BJ , Cuschieri KS , Rogovskaya SI , et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine 2013 Dec 31; 31(Suppl 7): H5970. https://doi.org/10.1016/j.vaccine.2013.03.029. PMID: 24332298.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Malignant neoplasms in Montenegro 2013. Podgorica: insitute of public health of Montenegro, center for control and prevention of non-communicable diseases, Registry of malignant neoplasms of Montenegro, 2018.

    • Search Google Scholar
    • Export Citation
  • 5.

    Ferlay J , Ervik M , Lam F , Colombet M , Mery L , Piñeros M , et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/today, accessed [08.06.2021].

    • Search Google Scholar
    • Export Citation
  • 6.

    Medeiros LR , Hilgert JB , Zanini RR , Berwanger O , Bozzetti MC , Mylius LC , et al. Vertical transmition of human papilloma virus: a systematic quantitive review. Cad Saude Publica 2005; 21(4): 100615.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    ZurHausen H. Papillomaviruses in the causation of human cancers e a brief historical account. Virology 2009; 384: 260e5. http://doi.org/10.1016/j.virol.2008.11.046.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lorenzi AT , Syrj€anen KJ , Longatto-filho A. Human papillomavirus (HPV) screening and cervical cancer burden. A Braz Perspect Virol J 2015; 1e6. http://doi.org/10.1186/s12985-015-0342-0.

    • Search Google Scholar
    • Export Citation
  • 9.

    ZurHausen H . Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55e78.

  • 10.

    Muñoz N , Bosch FX , de Sanjosé S , Herrero R , Castellsagué X , Shah KS , et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827. https://doi.org/10.1056/nejmoa021641.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Luostarinen T , Apter D , Dillner J , Eriksson T , Harjula K , Natunen K , et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer 2018; 142: 21867. https://doi.org/10.1002/ijc.31231.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Kim KS , Park S , Ko K-N , Yi S , Cho YJ . Current status of human papillomavirus vaccines. Clin Exp Vaccin Res 2014; 3(2): 16875.

  • 13.

    Pils S , Joura E . From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect 2015; 21(9): 82733.

  • 14.

    Krul EJ , Van De Vijver MJ , Schuuring E , Van Kanten RW , Peters AA , Fleuren GJ . Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to The Netherlands, a low-risk country. Int J Gynecol Cancer 1999; 9(3): 20611.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Vinodhini K , Shanmughapriya S , Das BC , Natarajaseenivasan K . Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstetr 2012; 285: 7717. https://doi.org/10.1007/s00404-011-2155-8.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Kovachev S , Slavov V , Slavova K . Prevalence of human papillomavirus infection in women in some cities and regions of Bulgaria. J Med Virol 2013; 85(9): 157784. https://doi.org/10.1002/jmv.23652.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Moga MA , Irimie M , Oanta A , Pascu A , Burtea V . Type-specific prevalence of human papillomavirus by cytology in Romania. Asian Pac J Cancer Prev 2014; 15(16): 688792. http://doi.org/10.7314/APJCP.2014.15.16.6887.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Tasic D , Lazarevic I , Knezevic A , Tasic L , Pikula A , Perisic Z , et al. The impact of environmental and behavioural cofactors on the development of cervical disorders in HR-HPV-infected women in Serbia. Epidemiol Infect 2018 Oct; 146(13): 171423. https://doi.org/10.1017/S0950268818001668. Epub 2018 Jun 20. PMID: 29923470.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Zejnullahu Raçi P , Hošnjak L , Poljak M , Lepej , Vince A . Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics. Ginekol Pol 2018; 89(9): 48594. https://doi.org/10.5603/GP.a2018.0083. PMID: 30318575.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    de Sanjosé S , Diaz M , Castellsagué X , Clifford G , Bruni L , Muñoz N , et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007 Jul; 7(7): 4539. https://doi.org/10.1016/S1473-3099(07)70158-5. PMID: 17597569.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Wagner M , Bennetts L , Patel H , Welner S , de Sanjose S , Weiss TW . Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. Infect Agent Cancer 2015 Apr 28; 10: 13. https://doi.org/10.1186/s13027-015-0008-y. PMID: 25987893; PMCID: PMC4435914.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Salimović-Bešić I , Hukić M . Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears. Epidemiol Infect 2015 Sep; 143(12): 260412. https://doi.org/10.1017/S0950268814003720. Epub 2015 Jan 12. PMID: 25578155.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Vujosević D , Vuksanović V , Poljak M , Jokmanović N . Human papillomavirus genotype spectrum in studied group of Montenegrin women. Acta Med (Hradec Kralove). 2012; 55(3): 1302. https://doi.org/10.14712/18059694.2015.50. PMID: 23297521.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Dabeski D , Dabeski A , Antovska V , Trajanova M , Todorovska I , Sima A . Human papillomavirus infections in women with and without squamous cell abnormalities of the uterine cervix. Scripta Med 2019; 50(2): 6976.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Filipi K , Tedeschini A , Paolini F , Celicu S , Morici S , Kota M , et al. Genital human papillomavirus infection and genotype prevalence among Albanian women: a cross-sectional study. J Med Virol 2010 Jul; 82(7): 11926. https://doi.org/10.1002/jmv.21803. PMID: 20513083.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    De Vuyst H , Clifford G , Li N , Franceschi S . HPV infection in Europe. Eur J Cancer 2009 Oct; 45(15): 26329. https://doi.org/10.1016/j.ejca.2009.07.019. Epub 2009 Aug 24. PMID: 19709878.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Sabol I , Milutin Gašperov N , Matovina M , Božinović K , Grubišić G , Fistonić I , et al. Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia. PLoS One 2017 Jul 10; 12(7): e0180480. https://doi.org/10.1371/journal.pone.0180480. PMID: 28692681; PMCID: PMC5503252.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Arbyn M , Benoy I , Simoens C , Bogers J , Beutels P , Depuydt C . Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Preven: A Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2009 Jan; 18(1): 32130. https://doi.org/10.1158/1055-9965.epi-08-0510. PMID: 19124515.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Clifford GM , Smith JS , Aguado T , Franceschi S . Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003 Jul 7; 89(1): 1015. https://doi.org/10.1038/sj.bjc.6601024. PMID: 12838308; PMCID: PMC2394204.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Karadža M , Židovec Lepej S , Planinić A , Grgić I , Ćorušić A , Planinić P , et al. Distribution of human papillomavirus genotypes in women with high-grade cervical intraepithelial lesions and cervical carcinoma and analysis of human papillomavirus-16 genomic variants. Croat Med J 2021 Feb 28; 62(1): 6879. https://doi.org/10.3325/cmj.2021.62.68. PMID: 33660963; PMCID: PMC7976879.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Forslund O , Antonsson A , Edlund K , van den Brule AJ , Hansson BG , Meijer CJ , et al. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002 Apr; 66(4): 53541. https://doi.org/10.1002/jmv.2178. Erratum in: J Med Virol 2002 Jul; 67(3): 467. PMID: 11857534.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Pista A , Oliveira A , Verdasca N , Ribeiro F . Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect 2011 Jun; 17(6): 9416. https://doi.org/10.1111/j.1469-0691.2010.03387.x. Epub 2010 Dec 3. PMID: 21040156.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Cuschieri KS , Cubie HA , Whitley MW , Seagar AL , Arends MJ , Moore C , et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004 Jan; 57(1): 6872. https://doi.org/10.1136/jcp.57.1.68. PMID: 14693839; PMCID: PMC1770158.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Balbi G , Napolitano A , Giordano F , Capuano S , Manganaro MA , Di Martino L , et al. Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions. Eur J Gynaecol Oncol 2012; 33(5): 46771. PMID: 23185789.

    • Search Google Scholar
    • Export Citation
  • 35.

    Liu Y , Ang Q , Wu H , Xu J , Chen D , Zhao H , et al. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China’s top 3 hospital, 2009-2019. Virol J 2020 Jul 13; 17(1): 104. https://doi.org/10.1186/s12985-020-01383-1. PMID: 32660490; PMCID: PMC7359485.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Bulkmans NW , Berkhof J , Bulk S , Bleeker MC , Van Kemenade FJ , Rozendaal L , et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419Y1424.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article (only for OA publications)
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2024 30 0 0
Sep 2024 40 0 0
Oct 2024 107 0 0
Nov 2024 56 0 0
Dec 2024 44 0 0
Jan 2025 51 0 0
Feb 2025 12 0 0